{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:08:47Z","timestamp":1783926527791,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP2453 project number 541742535"],"award-info":[{"award-number":["SPP2453 project number 541742535"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1451 project number 431549029"],"award-info":[{"award-number":["SFB1451 project number 431549029"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2030-390661388"],"award-info":[{"award-number":["EXC 2030-390661388"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2030-390661388"],"award-info":[{"award-number":["EXC 2030-390661388"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2067\/1-390729940"],"award-info":[{"award-number":["EXC 2067\/1-390729940"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR5762 project number 531902955"],"award-info":[{"award-number":["FOR5762 project number 531902955"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Huntington\u2019s disease (HD) is a hereditary movement disorder caused by a CAG repeat expansion in the\n                    <jats:italic>huntingtin<\/jats:italic>\n                    gene. HD is characterized by deposition of mutant huntingtin (mHTT) aggregates, and by severe neurodegeneration of the basal ganglia and neocortex. No cure is currently available, and new treatment options are urgently needed. Here, we show that the oligomer modifying molecule anle138b (INN: emrusolmin) improves multiple disease phenotypes in cell culture and in two mouse models of HD. Application of anle138b reduced mHTT aggregate formation and ameliorated neurotoxicity in primary neurons. Oral administration of anle138b delayed deposition of mHTT inclusions, reduced brain atrophy, mitigated neuroinflammation and transcriptional alterations, improved motor function and extended life span in HD mice. Downregulation of striatal markers and synapse loss in striatal spiny projection neurons were also partially rescued. No adverse effects of anle138b were observed in wildtype animals. Moreover, anle138b markedly decreased mHTT aggregation in human neural precursor cells differentiated from HD patient-derived induced pluripotent stem cells (iPSCs). Altogether these results illustrate the potential of anle138b as a disease-modifying treatment for HD.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00459-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:04:01Z","timestamp":1782464641000},"page":"2838-2866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington\u2019s disease"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-7163","authenticated-orcid":false,"given":"Miguel","family":"da Silva Padilha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Koyuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Chabanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Ryazanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-9382","authenticated-orcid":false,"given":"Andrei","family":"Leonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-0743","authenticated-orcid":false,"given":"David","family":"Vilchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-0163","authenticated-orcid":false,"given":"R\u00fcdiger","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-4344","authenticated-orcid":false,"given":"Christian","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1052-8485","authenticated-orcid":false,"given":"Irina","family":"Dudanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","unstructured":"Albariqi MMH, Baauw SMG, Fens SJPJ, Versteeg S, Ryazanov S, Leonov A, Willemen HLDM, Stathonikos N, Seychell RM, El Saghir A et al (2024) The amyloid oligomer modulator anle138b has disease modifying effects in a human IAPP transgenic mouse model of type 2 diabetes mellitus (hIAPP Ob\/Ob mice). Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.08.27.609850","DOI":"10.1101\/2024.08.27.609850"},{"key":"459_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4:595\u2013604","journal-title":"Lancet Psychiatry"},{"key":"459_CR3","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1073\/pnas.120166397","volume":"97","author":"JA Bibb","year":"2000","unstructured":"Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington\u2019s disease mice. Proc Natl Acad Sci USA 97:6809\u20136814","journal-title":"Proc Natl Acad Sci USA"},{"key":"459_CR4","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107260","volume":"40","author":"S Blumenstock","year":"2021","unstructured":"Blumenstock S, Schulz-Trieglaff EK, Voelkl K, Bolender AL, Lapios P, Lindner J, Hipp MS, Hartl FU, Klein R, Dudanova I (2021) Fluc-EGFP reporter mice reveal differential alterations of neuronal proteostasis in aging and disease. EMBO J 40:e107260","journal-title":"EMBO J"},{"key":"459_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-019-0522-z","volume":"11","author":"M Brendel","year":"2019","unstructured":"Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A et al (2019) Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer\u2019s disease tau. Alzheimers Res Ther 11:67","journal-title":"Alzheimers Res Ther"},{"key":"459_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43024-w","volume":"9","author":"J Burgold","year":"2019","unstructured":"Burgold J, Schulz-Trieglaff EK, Voelkl K, Gutierrez-Angel S, Bader JM, Hosp F, Mann M, Arzberger T, Klein R, Liebscher S et al (2019) Cortical circuit alterations precede motor impairments in Huntington\u2019s disease mice. Sci Rep 9:6634","journal-title":"Sci Rep"},{"key":"459_CR7","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","volume":"19","author":"RJ Carter","year":"1999","unstructured":"Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington\u2019s disease mutation. J Neurosci 19:3248\u20133257","journal-title":"J Neurosci"},{"key":"459_CR77","doi-asserted-by":"crossref","unstructured":"Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275\u2013280","DOI":"10.1038\/nbt.1529"},{"key":"459_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neuroimage.2005.01.039","volume":"26","author":"M Cyr","year":"2005","unstructured":"Cyr M, Caron MG, Johnson GA, Laakso A (2005) Magnetic resonance imaging at microscopic resolution reveals subtle morphological changes in a mouse model of dopaminergic hyperfunction. Neuroimage 26:83\u201390","journal-title":"Neuroimage"},{"key":"459_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537\u2013548","journal-title":"Cell"},{"key":"459_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nbd.2013.08.009","volume":"60","author":"YP Deng","year":"2013","unstructured":"Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A (2013) Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington\u2019s disease mice. Neurobiol Dis 60:89\u2013107","journal-title":"Neurobiol Dis"},{"key":"459_CR11","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"A Di Pardo","year":"2014","unstructured":"Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, Maglione V (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 23:2251\u20132265","journal-title":"Hum Mol Genet"},{"key":"459_CR12","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990\u20131993","journal-title":"Science"},{"key":"459_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15\u201321","journal-title":"Bioinformatics"},{"key":"459_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fncir.2013.00019","volume":"7","author":"AM Estrada-Sanchez","year":"2013","unstructured":"Estrada-Sanchez AM, Rebec GV (2013) Role of cerebral cortex in the neuropathology of Huntington\u2019s disease. Front Neural Circuits 7:19","journal-title":"Front Neural Circuits"},{"key":"459_CR15","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1093\/brain\/awh278","volume":"127","author":"CM Everett","year":"2004","unstructured":"Everett CM, Wood NW (2004) Trinucleotide repeats and neurodegenerative disease. Brain 127:2385\u20132405","journal-title":"Brain"},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/18796397251399751","volume":"15","author":"M Farag","year":"2026","unstructured":"Farag M, Tabrizi SJ, Wild EJ (2026) Huntington\u2019s disease clinical trials update: October 2025. J Huntingtons Dis 15:156\u2013166","journal-title":"J Huntingtons Dis"},{"key":"459_CR17","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","volume":"24","author":"RJ Ferrante","year":"2004","unstructured":"Ferrante RJ, Ryu H, Kubilus JK, D\u2019Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF et al (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease. J Neurosci 24:10335\u201310342","journal-title":"J Neurosci"},{"key":"459_CR18","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.3390\/ijms21218043","volume":"21","author":"P Gracia","year":"2020","unstructured":"Gracia P, Camino JD, Volpicelli-Daley L, Cremades N (2020) Multiplicity of alpha-synuclein aggregated species and their possible roles in disease. Int J Mol Sci 21:8043","journal-title":"Int J Mol Sci"},{"key":"459_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"459_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nmeth.1697","volume":"8","author":"R Gupta","year":"2011","unstructured":"Gupta R, Kasturi P, Bracher A, Loew C, Zheng M, Villella A, Garza D, Hartl FU, Raychaudhuri S (2011) Firefly luciferase mutants as sensors of proteome stress. Nat Methods 8:879\u2013884","journal-title":"Nat Methods"},{"key":"459_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","volume":"188","author":"RE Handsaker","year":"2025","unstructured":"Handsaker RE, Kashin S, Reed NM, Tan S, Lee WS, McDonald TM, Morris K, Kamitaki N, Mullally CD, Morakabati NR et al (2025) Long somatic DNA-repeat expansion drives neurodegeneration in Huntington\u2019s disease. Cell 188:623\u2013639.e619","journal-title":"Cell"},{"key":"459_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mdc3.13178","volume":"8","author":"S Hentosh","year":"2021","unstructured":"Hentosh S, Zhu L, Patino J, Furr JW, Rocha NP, Furr Stimming E (2021) Sex differences in Huntington\u2019s disease: evaluating the enroll-HD database. Mov Disord Clin Pract 8:420\u2013426","journal-title":"Mov Disord Clin Pract"},{"key":"459_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2019) Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 34:255\u2013263","journal-title":"Mov Disord"},{"key":"459_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1083\/jcb.201110093","volume":"196","author":"MS Hipp","year":"2012","unstructured":"Hipp MS, Patel CN, Bersuker K, Riley BE, Kaiser SE, Shaler TA, Brandeis M, Kopito RR (2012) Indirect inhibition of 26S proteasome activity in a cellular model of Huntington\u2019s disease. J Cell Biol 196:573\u2013587","journal-title":"J Cell Biol"},{"key":"459_CR25","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.celrep.2017.10.097","volume":"21","author":"F Hosp","year":"2017","unstructured":"Hosp F, Gutierrez-Angel S, Schaefer MH, Cox J, Meissner F, Hipp MS, Hartl FU, Klein R, Dudanova I, Mann M (2017) Spatiotemporal proteomic profiling of Huntington\u2019s disease inclusions reveals widespread loss of protein function. Cell Rep 21:2291\u20132303","journal-title":"Cell Rep"},{"key":"459_CR26","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"HY Hsiao","year":"2014","unstructured":"Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, Kuo HC, Chern Y (2014) Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum Mol Genet 23:4328\u20134344","journal-title":"Hum Mol Genet"},{"key":"459_CR27","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1152\/jn.01056.2014","volume":"113","author":"T Indersmitten","year":"2015","unstructured":"Indersmitten T, Tran CH, Cepeda C, Levine MS (2015) Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington\u2019s disease. J Neurophysiol 113:2953\u20132966","journal-title":"J Neurophysiol"},{"key":"459_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24411-2","volume":"12","author":"JM Isas","year":"2021","unstructured":"Isas JM, Pandey NK, Xu H, Teranishi K, Okada AK, Fultz EK, Rawat A, Applebaum A, Meier F, Chen J et al (2021) Huntingtin fibrils with different toxicity, structure, and seeding potential can be interconverted. Nat Commun 12:4272","journal-title":"Nat Commun"},{"key":"459_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR 3rd, Bordone L, Guarente L, Krainc D (2011) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18:159\u2013165","journal-title":"Nat Med"},{"key":"459_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"CG Keller","year":"2022","unstructured":"Keller CG, Shin Y, Monteys AM, Renaud N, Beibel M, Teider N, Peters T, Faller T, St-Cyr S, Knehr J et al (2022) An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun 13:1150","journal-title":"Nat Commun"},{"key":"459_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05320-3","volume":"9","author":"S Koyuncu","year":"2018","unstructured":"Koyuncu S, Saez I, Lee HJ, Gutierrez-Garcia R, Pokrzywa W, Fatima A, Hoppe T, Vilchez D (2018) The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington\u2019s disease patients. Nat Commun 9:2886","journal-title":"Nat Commun"},{"key":"459_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34419-x","volume":"13","author":"F Krach","year":"2022","unstructured":"Krach F, Stemick J, Boerstler T, Weiss A, Lingos I, Reischl S, Meixner H, Ploetz S, Farrell M, Hehr U et al (2022) An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington\u2019s disease patient neurons. Nat Commun 13:6797","journal-title":"Nat Commun"},{"key":"459_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","volume":"38","author":"J Labbadia","year":"2013","unstructured":"Labbadia J, Morimoto RI (2013) Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378\u2013385","journal-title":"Trends Biochem Sci"},{"key":"459_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa066","volume":"2","author":"C Landles","year":"2020","unstructured":"Landles C, Milton RE, Ali N, Flomen R, Flower M, Schindler F, Gomez-Paredes C, Bondulich MK, Osborne GF, Goodwin D et al (2020) Subcellular localization and formation of huntingtin aggregates correlates with symptom onset and progression in a Huntington\u2019S disease model. Brain Commun 2:fcaa066","journal-title":"Brain Commun"},{"key":"459_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nn.4256","volume":"19","author":"P Langfelder","year":"2016","unstructured":"Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, Lu XH, Ramos EM, El-Zein K, Zhao Y et al (2016) Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 19:623\u2013633","journal-title":"Nat Neurosci"},{"key":"459_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.neuron.2020.06.021","volume":"107","author":"H Lee","year":"2020","unstructured":"Lee H, Fenster RJ, Pineda SS, Gibbs WS, Mohammadi S, Davila-Velderrain J, Garcia FJ, Therrien M, Novis HS, Gao F et al (2020) Cell type-specific transcriptomics reveals that mutant huntingtin leads to mitochondrial RNA release and neuronal innate immune activation. Neuron 107:891\u2013908.e898","journal-title":"Neuron"},{"key":"459_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","volume":"127","author":"J Levin","year":"2014","unstructured":"Levin J, Schmidt F, Boehm C, Prix C, Botzel K, Ryazanov S, Leonov A, Griesinger C, Giese A (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127:779\u2013780","journal-title":"Acta Neuropathol"},{"key":"459_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104021","volume":"80","author":"J Levin","year":"2022","unstructured":"Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S et al (2022) Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine 80:104021","journal-title":"EBioMedicine"},{"key":"459_CR39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923\u2013930","journal-title":"Bioinformatics"},{"key":"459_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550","journal-title":"Genome Biol"},{"key":"459_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","volume":"411","author":"TC Ma","year":"2007","unstructured":"Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR (2007) Metformin therapy in a transgenic mouse model of Huntington\u2019s disease. Neurosci Lett 411:98\u2013103","journal-title":"Neurosci Lett"},{"key":"459_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506","journal-title":"Cell"},{"key":"459_CR43","doi-asserted-by":"crossref","unstructured":"Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 17:10\u201312","DOI":"10.14806\/ej.17.1.200"},{"key":"459_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.15252\/emmm.201707825","volume":"10","author":"A Martinez Hernandez","year":"2018","unstructured":"Martinez Hernandez A, Urbanke H, Gillman AL, Lee J, Ryazanov S, Agbemenyah HY, Benito E, Jain G, Kaurani L, Grigorian G et al (2018) The diphenylpyrazole compound anle138b blocks Abeta channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med 10:32\u201347","journal-title":"EMBO Mol Med"},{"key":"459_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","volume":"30","author":"N Masuda","year":"2008","unstructured":"Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington\u2019s disease. Neurobiol Dis 30:293\u2013302","journal-title":"Neurobiol Dis"},{"key":"459_CR46","doi-asserted-by":"publisher","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","volume":"7","author":"LB Menalled","year":"2012","unstructured":"Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K et al (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175. PLoS ONE 7:e49838","journal-title":"PLoS ONE"},{"key":"459_CR47","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nchembio.694","volume":"7","author":"J Miller","year":"2011","unstructured":"Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S et al (2011) Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol 7:925\u2013934","journal-title":"Nat Chem Biol"},{"key":"459_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2020.608060","volume":"14","author":"R Morigaki","year":"2020","unstructured":"Morigaki R, Lee JH, Yoshida T, Wuthrich C, Hu D, Crittenden JR, Friedman A, Kubota Y, Graybiel AM (2020) Spatiotemporal up-regulation of Mu opioid receptor 1 in striatum of mouse model of Huntington\u2019s disease differentially affecting caudal and striosomal regions. Front Neuroanat 14:608060","journal-title":"Front Neuroanat"},{"key":"459_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1471-4159.2001.00059.x","volume":"76","author":"AJ Morton","year":"2001","unstructured":"Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington\u2019s disease. J Neurochem 76:166\u2013172","journal-title":"J Neurochem"},{"key":"459_CR50","doi-asserted-by":"publisher","first-page":"12997","DOI":"10.1523\/JNEUROSCI.5284-12.2013","volume":"33","author":"RP Murmu","year":"2013","unstructured":"Murmu RP, Li W, Holtmaat A, Li JY (2013) Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington\u2019s disease. J Neurosci 33:12997\u201313009","journal-title":"J Neurosci"},{"key":"459_CR51","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/brain\/awv214","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F, Haider S, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini P, Kapur S, Rabiner EA et al (2015) Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease. Brain 138:3016\u20133029","journal-title":"Brain"},{"key":"459_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","volume":"12","author":"TH Palpagama","year":"2019","unstructured":"Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2019) The role of microglia and astrocytes in Huntington\u2019s disease. Front Mol Neurosci 12:258","journal-title":"Front Mol Neurosci"},{"key":"459_CR53","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","volume":"134","author":"IH Park","year":"2008","unstructured":"Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ (2008) Disease-specific induced pluripotent stem cells. Cell 134:877\u2013886","journal-title":"Cell"},{"key":"459_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cell.2013.06.003","volume":"154","author":"SH Park","year":"2013","unstructured":"Park SH, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, Hayer-Hartl M, Hartl FU (2013) PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell 154:134\u2013145","journal-title":"Cell"},{"key":"459_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","volume":"210","author":"Q Peng","year":"2008","unstructured":"Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model. Exp Neurol 210:154\u2013163","journal-title":"Exp Neurol"},{"key":"459_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.expneurol.2016.08.012","volume":"285","author":"C Reick","year":"2016","unstructured":"Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA (2016) Expression of brain-derived neurotrophic factor in astrocytes\u2014beneficial effects of glatiramer acetate in the R6\/2 and YAC128 mouse models of Huntington\u2019s disease. Exp Neurol 285:12\u201323","journal-title":"Exp Neurol"},{"key":"459_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","volume":"47","author":"A Reiner","year":"2012","unstructured":"Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP (2012) The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 47:75\u201391","journal-title":"Neurobiol Dis"},{"key":"459_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26684-z","volume":"12","author":"N Riguet","year":"2021","unstructured":"Riguet N, Mahul-Mellier AL, Maharjan N, Burtscher J, Croisier M, Knott G, Hastings J, Patin A, Reiterer V, Farhan H et al (2021) Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. Nat Commun 12:6579","journal-title":"Nat Commun"},{"key":"459_CR59","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","volume":"71","author":"DS Russell","year":"2014","unstructured":"Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S et al (2014) The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol 71:1520\u20131528","journal-title":"JAMA Neurol"},{"key":"459_CR60","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89:910\u2013926","journal-title":"Neuron"},{"key":"459_CR61","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"459_CR62","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1093\/hmg\/ddw212","volume":"25","author":"AL Southwell","year":"2016","unstructured":"Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S et al (2016) An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum Mol Genet 25:3654\u20133675","journal-title":"Hum Mol Genet"},{"key":"459_CR63","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.neuroscience.2008.09.020","volume":"157","author":"J Spampanato","year":"2008","unstructured":"Spampanato J, Gu X, Yang XW, Mody I (2008) Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington\u2019s disease. Neuroscience 157:606\u2013620","journal-title":"Neuroscience"},{"key":"459_CR76","doi-asserted-by":"crossref","unstructured":"Speranza L, Filiz KD, Goebel S, Perrone-Capano C, Pulcrano S, Volpicelli F, Francesconi A (2022) Combined DiI and Antibody Labeling Reveals Complex Dysgenesis of Hippocampal Dendritic Spines in a Mouse Model of Fragile X Syndrome. Biomedicines 10","DOI":"10.1101\/2022.09.20.508741"},{"key":"459_CR64","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/jcmm.12604","volume":"19","author":"F Squitieri","year":"2015","unstructured":"Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L (2015) Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J Cell Mol Med 19:2540\u20132548","journal-title":"J Cell Mol Med"},{"key":"459_CR65","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12035-018-1126-5","volume":"56","author":"N Suelves","year":"2019","unstructured":"Suelves N, Miguez A, Lopez-Benito S, Barriga GG, Giralt A, Alvarez-Periel E, Arevalo JC, Alberch J, Gines S, Brito V (2019) Early downregulation of p75(NTR) by genetic and pharmacological approaches delays the onset of motor deficits and striatal dysfunction in Huntington\u2019s disease mice. Mol Neurobiol 56:935\u2013953","journal-title":"Mol Neurobiol"},{"key":"459_CR66","doi-asserted-by":"crossref","unstructured":"Swanson MEV, Tan AYS, Tippett LJ, Turner C, Curtis MA, Scotter E, Lashuel H, Dragunow M, Faull RM, Murray HC et al (2025) Huntingtin inclusion bodies have distinct immunophenotypes and ubiquitination profiles in the Huntington\u2019s disease human cerebral cortex. Sci Rep 15:15546","DOI":"10.1038\/s41598-025-00465-w"},{"key":"459_CR67","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16:529\u2013546","DOI":"10.1038\/s41582-020-0389-4"},{"key":"459_CR68","doi-asserted-by":"publisher","first-page":"e202409104","DOI":"10.1083\/jcb.202409104","volume":"224","author":"V Uytterhoeven","year":"2025","unstructured":"Uytterhoeven V, Verstreken P, Nachman E (2025) Synaptic sabotage: how Tau and alpha-Synuclein undermine synaptic health. J Cell Biol 224:e202409104","journal-title":"J Cell Biol"},{"key":"459_CR69","doi-asserted-by":"publisher","first-page":"e202302018","DOI":"10.26508\/lsa.202302018","volume":"6","author":"K Voelkl","year":"2023","unstructured":"Voelkl K, Gutierrez-Angel S, Keeling S, Koyuncu S, da Silva Padilha M, Feigenbutz D, Arzberger T, Vilchez D, Klein R, Dudanova I (2023) Neuroprotective effects of hepatoma-derived growth factor in models of Huntington\u2019s disease. Life Sci Alliance 6:e202302018","journal-title":"Life Sci Alliance"},{"key":"459_CR70","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","volume":"130","author":"J Wagner","year":"2015","unstructured":"Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A, Kleinknecht A, Goricke B, Weishaupt JH et al (2015) Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol 130:619\u2013631","journal-title":"Acta Neuropathol"},{"key":"459_CR71","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813","journal-title":"Acta Neuropathol"},{"key":"459_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/7854_2014_354","volume":"22","author":"HJ Waldvogel","year":"2015","unstructured":"Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel JP, Faull RL (2015) The neuropathology of Huntington\u2019s disease. Curr Top Behav Neurosci 22:33\u201380","journal-title":"Curr Top Behav Neurosci"},{"key":"459_CR73","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","volume":"138","author":"M Wegrzynowicz","year":"2019","unstructured":"Wegrzynowicz M, Bar-On D, Calo L, Anichtchik O, Iovino M, Xia J, Ryazanov S, Leonov A, Giese A, Dalley JW et al (2019) Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model. Acta Neuropathol 138:575\u2013595","journal-title":"Acta Neuropathol"},{"key":"459_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104963","volume":"143","author":"DK Wilton","year":"2020","unstructured":"Wilton DK, Stevens B (2020) The contribution of glial cells to Huntington\u2019s disease pathogenesis. Neurobiol Dis 143:104963","journal-title":"Neurobiol Dis"},{"key":"459_CR75","doi-asserted-by":"crossref","unstructured":"Xu X, Tay Y, Sim B, Yoon SI, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C et al (2017) Reversal of Phenotypic Abnormalities by CRISPR\/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports 8:619\u2013633","DOI":"10.1016\/j.stemcr.2017.01.022"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00459-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00459-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00459-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:31:37Z","timestamp":1783924297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00459-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,13]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00459-9","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AG and CG are co-founders and shareholders of MODAG. AG is a full-time employee of MODAG. AL and SR are partly employed by MODAG and are beneficiaries of the phantom share program of MODAG GmbH. AL, SR, CG, and AG are co-inventors of WO\/2010\/000372. Anle138b is licensed by Teva Pharmaceutical Industries Ltd and is in clinical development in collaboration with MODAG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}